New Sjögren's drug candidate tested for safety in Early-Stage trial
NCT ID NCT06544642
First seen Oct 31, 2025 · Last updated Apr 28, 2026 · Updated 22 times
Summary
This early-stage study tested a new drug called ASP5502 in healthy adults and people with Sjögren's syndrome, a condition where the immune system attacks moisture-producing glands. The main goal was to check safety and how well the drug is tolerated. The study was terminated, so results are not available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Fortrea Clinical Research Unit Inc
Daytona Beach, Florida, 32117, United States
Conditions
Explore the condition pages connected to this study.